JNTU B.Pharmacy III GENERIC PRODUCT DEVELOPMENT Previous Question Paper (October/November-2020 - R17)

The Hatch-Waxman Act, officially known as the Drug Price Competition and Patent Term Restoration Act of 1984, is a landmark piece of legislation in the United States that established the modern framework for the generic drug industry. It aimed to balance the need for encouraging pharmaceutical innovation with the need to provide affordable generic alternatives to the public.

Key provisions of the Act include:

• Abbreviated New Drug Application (ANDA): It created a streamlined approval process for generic drugs, allowing manufacturers to rely on the safety and efficacy data of the innovator's drug (Reference Listed Drug) rather than conducting independent clinical trials.
• Patent Term Restoration: It allowed brand-name manufacturers to extend their patent life to compensate for time lost during the lengthy FDA clinical trial and approval process, typically up to five years.
• Exclusivity Periods: The Act introduced market exclusivity periods, such as the 180-day exclusivity granted to the first generic applicant to successfully challenge a patent, incentivizing generic companies to pursue patent litigation.
• Bolar Provision: This allows generic manufacturers to perform necessary research and testing for FDA approval before the innovator's patent expires, without being considered patent infringement.

Significant amendments and related legislative updates include:

• Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003: This amendment addressed loopholes in the original Act, particularly regarding the 30-month stay of approval. It limited brand companies to a single 30-month stay per ANDA for patent infringement litigation and introduced requirements for reporting patent settlement agreements to the Federal Trade Commission to prevent anti-competitive 'pay-for-delay' deals.
• FDA Amendments Act (FDAAA) of 2007: This strengthened the FDA's authority regarding drug safety, including the requirement for Risk Evaluation and Mitigation Strategies (REMS), which generic manufacturers must also comply with to ensure the safe use of their products.
• Generic Drug User Fee Act (GDUFA): Although not a direct amendment to the original text, GDUFA established a system of user fees for generic drug applicants to provide the FDA with resources to expedite the review process and improve the quality of generic drug submissions.